Stock DNA
Pharmaceuticals & Biotechnology
SEK 199 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-1.50
-169.55%
3.68
Revenue and Profits:
Net Sales:
20 Million
(Quarterly Results - Jun 2025)
Net Profit:
-32 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-15.04%
0%
-15.04%
6 Months
-65.45%
0%
-65.45%
1 Year
-80.29%
0%
-80.29%
2 Years
-63.26%
0%
-63.26%
3 Years
-93.77%
0%
-93.77%
4 Years
-94.87%
0%
-94.87%
5 Years
-94.29%
0%
-94.29%
IRLAB Therapeutics AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
144.04%
EBIT Growth (5y)
3.39%
EBIT to Interest (avg)
-41.40
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-5.36
Sales to Capital Employed (avg)
0.65
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
2.69%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-8.24
EV to EBIT
-2.51
EV to EBITDA
-2.63
EV to Capital Employed
-33.71
EV to Sales
3.28
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Bearish
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
19.50
4.40
343.18%
Operating Profit (PBDIT) excl Other Income
-22.70
-28.50
20.35%
Interest
7.00
5.60
25.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-32.30
-34.00
5.00%
Operating Profit Margin (Excl OI)
-1,220.10%
-6,793.80%
557.37%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 343.18% vs -89.72% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 5.00% vs -529.63% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
94.60
5.70
1,559.65%
Operating Profit (PBDIT) excl Other Income
-87.80
-175.80
50.06%
Interest
10.50
0.20
5,150.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-83.10
-177.80
53.26%
Operating Profit Margin (Excl OI)
-976.70%
-31,724.60%
3,074.79%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 1,559.65% vs -90.67% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 53.26% vs -56.79% in Dec 2023
About IRLAB Therapeutics AB 
IRLAB Therapeutics AB
Pharmaceuticals & Biotechnology
IRLAB Therapeutics AB is a Sweden-based research and development company. It focuses on illnesses in the central nervous system and primarily on development of drugs to assist patients with Parkinson’s disease. The Company possesses a research platform Integrative Screening Process (ISP), which aims to discover and develop drug candidates for the treatment of brain diseases. The Company operates projects on both clinical phase and preclinical phases. The primary projects are IRL790 and IRL752, both on clinical phase. The IRL790 project is a psychomotor stabilizer for the treatment of levodopa (L-dopa) amino acid that dyskinesia induces in Parkinson’s Disease (PD-LIDs) and Parkinson Disease psychosis (PD-Psychosis). The IRL752 project aims at cortical enhancement for the treatment of Parkinson Disease Dementia (PD-D) and Behavioral and Psychological Symptoms of Dementia (BPSD).
Company Coordinates 
Company Details
Arvid Wallgrens Backe 20 , GOETEBORG None : 413 46
Registrar Details






